QS - please correct your misstatements:
"Rainbow BioSciences, is making some big moves in the sector by joint venturing with hot properties that have short-term marketability and commercialization potential" - RBCC has no such joint ventures.
"RBCC is a tip-of-the-spear company pioneering new medical territory in a global biotech market" - RBCC is not a pioneer. In fact the sole employee has no experience in this field. His only experience stated in the 10K is in renewable energy projects.
"A similar JV framework was arrived at previously for AMBS’s Parkinson’s disease and traumatic brain/nervous system injury diagnostic offering, NuroPro..." - RBCC has no such JV.
"The AMBS relationship is a perfect example of the cunning strategic savvy already demonstrated by RBCC..." - no such relationship has been formed yet.
"San Francisco-based biotech player RBCC will be making the rounds at the upcoming Biotech Showcase™ 2013 and has an established track-record of mining such venues..." - RBCC is not San Francisco based, nor do they have ANY track record of mining such venues. RBCC operates out of a strip mall with virtual office space in Miramar, Florida.
"Another example of the relentless drive by RBCC to seek out new medical and research technology innovations is the extensive work with JV partner Nano3D Biosciences (n3D)..." - RBCC has not provided any technical work to n3D and is NOT a JV partner with them. RBCC has contributed a measley $413.62 (out of $249,826 total committed) towards eventually purchasing up to 5% of n3D's privately held company.
"...investors would be wise to follow the wider industry’s lead in anticipating explosive growth from RBCC, as the company has quickly put together a considerable tech footprint that stretches across entire sectors" - investors should take note that RBCC has no such footprint in any sector.
"RBCC’s equity interest gives shareholders a de-risked vector for short-term viable returns..." - ooooh, such fancy terms "de-risked vector"! Unfortunately, the equity interest in n3D only amounts to a 0.008% interest to date.
